Evidence map›Paper›PMID 40821429›Full record

ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2025

A Pilot Assessment of Caregivers' and Patients' Perception of Naloxone Coprescribing in a Pediatric Sickle Cell Population.

Elizabeth B Ferengul, Lauren M Oliveri, Leslie Briars, Lewis L Hsu, Paige Reilly, Sara W Hovey

Abstract read
In one paragraph

Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elizabeth B FerengulDepartment of Pharmacy Practice (EBF, SWH, LB, LMO), University of Illinois Chicago, Department of Pediatrics, Division of Hematology-Oncology (LLH, PR), University of Illinois Chicago, Chicago, IL.
Lauren M OliveriDepartment of Pharmacy Practice (EBF, SWH, LB, LMO), University of Illinois Chicago, Department of Pediatrics, Division of Hematology-Oncology (LLH, PR), University of Illinois Chicago, Chicago, IL.
Leslie BriarsDepartment of Pharmacy Practice (EBF, SWH, LB, LMO), University of Illinois Chicago, Department of Pediatrics, Division of Hematology-Oncology (LLH, PR), University of Illinois Chicago, Chicago, IL.
Lewis L HsuDepartment of Pharmacy Practice (EBF, SWH, LB, LMO), University of Illinois Chicago, Department of Pediatrics, Division of Hematology-Oncology (LLH, PR), University of Illinois Chicago, Chicago, IL.
Paige ReillyDepartment of Pharmacy Practice (EBF, SWH, LB, LMO), University of Illinois Chicago, Department of Pediatrics, Division of Hematology-Oncology (LLH, PR), University of Illinois Chicago, Chicago, IL.
Sara W HoveyDepartment of Pharmacy Practice (EBF, SWH, LB, LMO), University of Illinois Chicago, Department of Pediatrics, Division of Hematology-Oncology (LLH, PR), University of Illinois Chicago, Chicago, IL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe purpose of this survey was to evaluate knowledge and perception of naloxone among patients with sickle cell disease and their caregivers.

methodsA 13-question survey about naloxone and the subject's perception of naloxone was developed by the research team and reviewed by 5 advocates for pediatric patients with sickle cell disease. The survey was offered to patient-caregivers and patients ≥12 years old with sickle cell disease and a prescription for home opioid medication. The survey was conducted during a clinic visit or inpatient admission with a convenience sampling strategy.

resultsA total of 23 surveys were completed (9 patients and 14 caregivers). Nine of 23 subjects (40%) said they had heard of naloxone. Three subjects had naloxone at home. Only 3 caregivers said having naloxone at home would change their opioid use behavior.

conclusionThere is a lack of awareness about naloxone in the pediatric sickle cell disease population. Those who were aware of naloxone did feel it was an important medication and appeared to have a positive view of it.

Indexed as

coprescriptionnaloxoneopioidspediatricssickle cell disease

Identifiers

PMID40821429
PMCPMC12351457

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.